GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Abattis Bioceuticals Corp (OTCPK:ATTBF) » Definitions » Gross Profit

Abattis Bioceuticals (Abattis Bioceuticals) Gross Profit : $0.18 Mil (TTM As of Sep. 2019)


View and export this data going back to . Start your Free Trial

What is Abattis Bioceuticals Gross Profit?

Abattis Bioceuticals's gross profit for the three months ended in Sep. 2019 was $0.12 Mil. Abattis Bioceuticals's gross profit for the trailing twelve months (TTM) ended in Sep. 2019 was $0.18 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Abattis Bioceuticals's gross profit for the three months ended in Sep. 2019 was $0.12 Mil. Abattis Bioceuticals's Revenue for the three months ended in Sep. 2019 was $0.17 Mil. Therefore, Abattis Bioceuticals's Gross Margin % for the quarter that ended in Sep. 2019 was 71.35%.

Abattis Bioceuticals had a gross margin of 71.35% for the quarter that ended in Sep. 2019 => Durable competitive advantage


Abattis Bioceuticals Gross Profit Historical Data

The historical data trend for Abattis Bioceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abattis Bioceuticals Gross Profit Chart

Abattis Bioceuticals Annual Data
Trend Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 - - 0.01 0.18

Abattis Bioceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.06 0.12

Competitive Comparison of Abattis Bioceuticals's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Abattis Bioceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abattis Bioceuticals's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Abattis Bioceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Abattis Bioceuticals's Gross Profit falls into.



Abattis Bioceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Abattis Bioceuticals's Gross Profit for the fiscal year that ended in Sep. 2019 is calculated as

Gross Profit (A: Sep. 2019 )=Revenue - Cost of Goods Sold
=0.27 - 0.088
=0.18

Abattis Bioceuticals's Gross Profit for the quarter that ended in Sep. 2019 is calculated as

Gross Profit (Q: Sep. 2019 )=Revenue - Cost of Goods Sold
=0.171 - 0.049
=0.12

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.18 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Abattis Bioceuticals's Gross Margin % for the quarter that ended in Sep. 2019 is calculated as

Gross Margin % (Q: Sep. 2019 )=Gross Profit (Q: Sep. 2019 ) / Revenue (Q: Sep. 2019 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.12 / 0.171
=71.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Abattis Bioceuticals  (OTCPK:ATTBF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Abattis Bioceuticals had a gross margin of 71.35% for the quarter that ended in Sep. 2019 => Durable competitive advantage


Abattis Bioceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Abattis Bioceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Abattis Bioceuticals (Abattis Bioceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1200 - 625 Howe Street, Vancouver, BC, CAN, V6C 2M6
Abattis Bioceuticals Corp is a Canadian life science and biotechnology company focuses on aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry. It is primarily engaged in producing, licensing and marketing proprietary ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The company is also engaged in growing, extraction, testing, propagation and online distribution.

Abattis Bioceuticals (Abattis Bioceuticals) Headlines

From GuruFocus

Abattis Comments on BCSC Temporary Order

By Marketwired Marketwired 11-28-2018

Abattis Removed From BCSC Temporary Order

By Marketwired Marketwired 01-17-2019

Abattis Provides Update on Conference Call

By Marketwired Marketwired 02-28-2019

Abattis Bioceuticals Celebrates Legalization

By Marketwired Marketwired 10-18-2018

Abattis Bioceuticals Provides Update on Vaporizer Product Line

By Marketwired Marketwired 10-12-2018